CP and bacterial infectious disease with sepsis: In a multicentric retrospective study, ceftazidime-avibactam monotherapy, ceftazidime-avibactam combination therapy and meropenem-vaborbactam monotherapy have been compared in patients with severe CRE infections, including bacteremia mainly caused by K. pneumoniae-CP and no significant difference in clinical success and mortality rate was observed even though patients in the meropenem-vaborbactam arm received combination therapy more rarely than in the ceftazidime-avibactam arm [31].